CLX's GOJO deal boosts fiscal 2027 sales, but inflation, acquisition costs and margin pressure could limit underlying growth.

CLX's GOJO-led growth faces margin pressure, muted core demand and inflation risks, leaving investors focused on a durable recovery.

CLX's rebound faces margin pressure, muted underlying demand and weaker earnings revisions despite GOJO and ERP tailwinds.

I reiterate a Hold rating on The Clorox Company, as the current valuation requires unsustainably high free cash flow growth. Recent positives include the GOJO acquisition and ERP rollout, but organic revenue growth remains limited after adjusting for these factors. CLX's balance sheet is heavily leveraged post-acquisition, constraining reinvestment and raising dividend sustainability concerns.

OAKLAND, Calif., Aug. 19, 2026 /PRNewswire/ -- The Clorox Company (NYSE: CLX) today announced that Chair and Chief Executive Officer Linda Rendle and Chief Financial Officer Luc Bellet will participate in a fireside chat at the Barclays Global Consumer Staples Conference on Wednesday, September 9, in Boston.

Investors interested in stocks from the Consumer Products - Staples sector have probably already heard of Newell Brands (NWL) and Clorox (CLX). But which of these two companies is the best option for those looking for undervalued stocks?

Clorox beats Q4 sales and earnings estimates as GOJO boosts sales, but lower volume and rising costs pressure margins and profits.

Clorox sees fiscal 2027 sales rising on GOJO and ERP comparisons, but inflation, muted categories and value-seeking consumers cloud the recovery.

Clorox Co (NYSE:CLX) reported better-than-expected earnings for the fourth quarter on Monday.

The Clorox Company reported volatile fiscal Q4 earnings, reflecting the recent GOJO acquisition and ERP disruption. Underneath transitory factors, CLX's organic sales performance is weak. Private label brands weigh on CLX's brand portfolio. CLX hasn't been able to shift increased input costs into prices.